Join the PANTS Study!
Inclusion of patients receiving Biosimilar Infliximab - Remsima™ & Inflectra™
Dr Tariq Ahmad
The latest version of the PANTS protocol allows the inclusion of Crohn's disease patients receiving Biosimilar Infliximab. Specifically this allows
- Inclusion of anti-TNF naive Crohn's disease patients starting Remsima™ or Inflectra™
- Existing PANTS study participants receiving RemicadeTM to switch to Remsima™ or Inflectra™
The PANTS study is a prospective uncontrolled cohort study investigating primary non-response, loss of response and adverse drug reactions to Infliximab and Adalimumab in patients with severe active luminal Crohn's disease. The study started in March 2013 and to date 1200 patients aged over 6 years have been recruited from 118 UK hospitals. The collection of clinical data is aligned and shared with the Royal College of Physicians UK IBD Biologics Audit (and in due course with the UK IBD registry), and individual patient laboratory data is released on the web portal.
Biosimilar Infliximab became available in the UK in February 2015 offering significant savings to the National Health Service. Extensive non-clinical and clinical data have shown comparability with the reference product, Remicade™. However the clinical data to date has emerged from the use of Biosimilar Infliximab in studies of patients with Ankylosing Spondylitis and Rheumatoid Arthritis. The PANTS study will report the initial UK experience of Biosimilar Infliximab in Crohn's disease, providing important post-authorisation data on efficacy (at week 14, 30 and 54), safety (to 3 years) and pharmacokinetics. We aim to include 225 patients treated with Biosimilar Infliximab as first-line anti-TNF treatment and 100 PANTS "switchers" over the next 12 months. Please do consider recruiting your patients to the PANTS study.
Recruitment for PPALM Study
Refer your patients with radiotherapy-induced bleeding
This randomised, double-blind, placebo-controlled, NIHR-approved trial is recruiting patients with new-onset rectal bleeding affecting quality of life and due to radiation-induced telangiectasia who are free of other abnormal GI symptoms.
For further details or to arrange referral contact:
Jennifer Matthews, trial coordinator
Tel: 0207 352 8171 ext. 1515
Recruitment deadline: January 2016
- Further information [ 40 kb ]
Paediatric European Digestive Diseases Clinical Research Network – PEDDCReN
PEDDCReN was an exciting new initiative with the key aim of forming a clinical trials network to study (and ultimately provide) effective medicines for paediatric patients in the speciality of Gastroenterology, Hepatology and Nutrition. It was established with the support of LINK funding from the UEG and was led by the BSG in collaboration with various European societies and ENPR-EMA (The European Network of Paediatric Research at the European Medicines Agency). The project supported both industry and non-industry investigators in running high quality multi-centre clinical trials. The final report has now been published.
- Further information [ 780 kb ]
HCV clinical trial and tissue biobank
IBD Nixon Twin and Multiplex Registry
Page 1 of 3